SNCB Recombinant Protein

Recombinant full length human SNCB was expressed in E. coli cells using an N-terminal His tag.

Scientific Background: SNCB is a member of the synuclein family of proteins which are believed to be involved in the pathogenesis of neurodegenerative diseases. SNCB is highly homologous to alpha-synuclein which is abundantly expressed in the brain and putatively inhibits phospholipase D2 selectively. SNCB may play a role in neuronal plasticity, is abundant in neurofibrillary lesions of patients with Alzheimer disease. SNCB is shown to be highly expressed in the substantia nigra of the brain, a region of neuronal degeneration in patients with Parkinson disease but no direct relation to Parkinson disease has been established (1). An alteration in SNCB may impair its normal inhibitory action on the formation of toxic alpha-synuclein fibrils, thereby indirectly contributing to disease pathogenesis (2).

1. Ohtake, H. et.al: Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63: 805-811, 2004.
2. Lavedan, C. et.al: Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res. 5: 401-402, 1998.

Small volumes of SNCB recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS515405 is a recombinant protein targeting SNCB. Host: E Coli.